Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
venBio Partners LLC (CIK 1776382) reported $280.6M across 6 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: PHVS ($131.1M, 46.71%), ALMS ($99.8M, 35.56%), ALXO ($25.8M, 9.21%), HRMY ($13.7M, 4.88%), LYEL ($6.8M, 2.41%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PHVS | PHARVARIS N V | $131.1M | 46.71% | 4.6M | Hold |
| 2 | ALMS | ALUMIS INC | $99.8M | 35.56% | 4.5M | Trimmed |
| 3 | ALXO | ALX ONCOLOGY HLDGS INC | $25.8M | 9.21% | 12.9M | Added |
| 4 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $13.7M | 4.88% | 489,194 | Hold |
| 5 | LYEL | LYELL IMMUNOPHARMA INC | $6.8M | 2.41% | 337,697 | Hold |
| 6 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $3.4M | 1.22% | 531,337 | Trimmed |
Source: SEC Form 13F filings · as of 2026-03-31